Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT-2 inhibitors as cardio-renal protective agents
Irene Caruso, Francesco Giorgino
Metabolism (2021) Vol. 127, pp. 154937-154937
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

New strategies to improve clinical outcomes for diabetic kidney disease
Thomas Först, Chantal Mathieu, Francesco Giorgino, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 66
Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports
Hiroyuki Seki, Satoshi Ideno, Toshiya Shiga, et al.
Journal of Anesthesia (2023) Vol. 37, Iss. 3, pp. 465-473
Open Access | Times Cited: 25
Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future
Irene Caruso, Francesco Giorgino
Endocrine (2024) Vol. 84, Iss. 3, pp. 822-835
Open Access | Times Cited: 13
Asymptomatic Hyperuricemia and the Kidney: Lessons from the URRAH Study
Cecilia Barnini, Elisa Russo, Giovanna Leoncini, et al.
Metabolites (2025) Vol. 15, Iss. 1, pp. 11-11
Open Access | Times Cited: 1
Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials
Yuxin Zhang, Zhaoji Li, Yongchen Hao
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access | Times Cited: 1
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
Marta Baviera, Andreana Foresta, Pierluca Colacioppo, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 29
Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
Rosaria Vincenza Giglio, Angelo Maria Patti, Ali A. Rizvi, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 291-291
Open Access | Times Cited: 19
Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome
Ioannis Lempesis, Samuel J. Apple, Gustavo Duarte, et al.
Diabetes/Metabolism Research and Reviews (2023) Vol. 39, Iss. 6
Open Access | Times Cited: 14
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease
Xianhua Mao, Xinrong Zhang, Leslie Y. Kam, et al.
Gut (2024) Vol. 73, Iss. 12, pp. 2054-2061
Closed Access | Times Cited: 5
Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis
Saixian Shi, Xiaofeng Li, Ye Chen, et al.
Journal of Diabetes (2025) Vol. 17, Iss. 1
Open Access
Mutual Regulation between Redox and Hypoxia-Inducible Factors in Cardiovascular and Renal Complications of Diabetes
Carla Iacobini, Martina Vitale, Jonida Haxhi, et al.
Antioxidants (2022) Vol. 11, Iss. 11, pp. 2183-2183
Open Access | Times Cited: 20
Liver fat as risk factor of hepatic and cardiometabolic diseases
Münevver Demir, Stefan R. Bornstein, Christos S. Mantzoros, et al.
Obesity Reviews (2023) Vol. 24, Iss. 10
Open Access | Times Cited: 12
Exploration of metformin-based drug combination for mitigating diabetes-associated atherosclerotic diseases
Biao Qu, Zheng Li, Wei‐Syun Hu
World Journal of Diabetes (2025) Vol. 16, Iss. 4
Closed Access
Heart Failure in Older Patients: An Update
Massimo Montalto, Federica D’Ignazio, Sara Camilli, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1982-1982
Open Access
The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats
Alana Aragón‐Herrera, Sandra Moraña‐Fernández, Manuel Otero-Santiago, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114535-114535
Open Access | Times Cited: 10
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
Anjay Rastogi, James L. Januzzi
Journal of Clinical Medicine (2023) Vol. 12, Iss. 8, pp. 2824-2824
Open Access | Times Cited: 9
Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
Angelo Cignarelli, Valentina Annamaria Genchi, Giulia Le Grazie, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 15
A new perspective on proteinuria and drug therapy for diabetic kidney disease
Ruimin Zhang, Qian Wang, Yaqing Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis
Mehmet Kanbay, Crischentian Brinza, Sidar Çöpür, et al.
Nephrology Dialysis Transplantation (2024)
Closed Access | Times Cited: 2
Sodium–glucose cotransporter 2 inhibitors in horses—Magic bullet or latest fad?
Tania Sundra, Guy D. Lester, Gabriele Rossi, et al.
Equine Veterinary Journal (2023) Vol. 55, Iss. 4, pp. 559-562
Closed Access | Times Cited: 5
Designer GLP1 poly-agonist peptides in the management of diabesity
Laura Statham, Melina Pelling, Petra Hanson, et al.
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 3, pp. 231-240
Open Access | Times Cited: 4
New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
Cheng‐Hsien Hung, Li‐Yu Lu
Neurology International (2024) Vol. 16, Iss. 6, pp. 1717-1730
Open Access | Times Cited: 1
Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
Ai‐Yu Yang, Hung‐Chun Chen
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 6
Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Yang Wang, Ning Xia
Hormone and Metabolic Research (2022) Vol. 54, Iss. 12, pp. 833-844
Closed Access | Times Cited: 5
Understanding Proteinuria in Patients with Diabetic Kidney Disease and Progress of Drug Therapy from a New Perspective
Ruimin Zhang, Qian Wang, Xuefeng Zhou, et al.
(2023)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top